Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Acute lymphocytic leukaemia
ADR ID BADD_A00077
ADR Hierarchy
01      Blood and lymphatic system disorders
01.10      Leukaemias
01.10.01      Leukaemias acute lymphocytic
01.10.01.001      Acute lymphocytic leukaemia
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.01      Leukaemias
16.01.01      Leukaemias acute lymphocytic
16.01.01.001      Acute lymphocytic leukaemia
Description A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. | When the disease process is confined to a mass lesion with no or minimal evidence of blood and less than 25% marrow involvement, the diagnosis is lymphoblastic lymphoma; with blood and greater than 25% marrow involvement, ALL is the appropriate term. [MeSH]
MedDRA Code 10000846
MeSH ID D054198
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Acute lymphatic leukaemia | Acute lymphatic leukemia | Acute lymphoblastic leukaemia | Acute lymphoblastic leukemia | Acute lymphocytic leukaemia | Acute lymphocytic leukemia | Acute lymphoid leukaemia | Acute lymphoid leukemia without mention of remission | ALL | Leukemia lymphoblastic acute | Lymphoid leukaemia, acute | Lymphoid leukemia, acute | Receptor silent type acute leukaemia | Receptor silent type acute leukemia | Acute lymphoid leukaemia without mention of remission | Leukaemia lymphoblastic acute | Acute lymphoid leukemia | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Precursor Cell Lymphoblastic Leukemia Lymphoma | Leukemia, Acute Lymphoblastic | Acute Lymphoblastic Leukemia | Leukemia, Lymphoblastic | Leukemia, Lymphoblastic, Acute | Leukemia, Lymphocytic, Acute | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute | Lymphoblastic Lymphoma | Lymphocytic Leukemia, Acute | Acute Lymphocytic Leukemia | Leukemia, Acute Lymphocytic | Lymphoma, Lymphoblastic | Acute Lymphoid Leukemia | Leukemia, Acute Lymphoid | Lymphoid Leukemia, Acute | Leukemia, Lymphoid, Acute | Leukemia, Lymphocytic, Acute, L1 | Lymphocytic Leukemia, L1 | L1 Lymphocytic Leukemia | Leukemia, L1 Lymphocytic | Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia, Acute, L1 | ALL, Childhood | Childhood ALL | Leukemia, Lymphoblastic, Acute, L1 | Leukemia, Lymphocytic, Acute, L2 | Lymphocytic Leukemia, L2 | L2 Lymphocytic Leukemia | Leukemia, L2 Lymphocytic | Lymphoblastic Leukemia, Acute, Adult | Lymphoblastic Leukemia, Acute, L2 | Leukemia, Lymphoblastic, Acute, L2 | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00194Azacitidine0.000224%
BADD_D00284Bortezomib0.000168%
BADD_D00286Bosutinib0.000414%
BADD_D00356Carbamazepine0.000372%
BADD_D00364Carboplatin0.000224%
BADD_D00367Carfilzomib0.000112%
BADD_D00511Clozapine0.004280%
BADD_D00589Dasatinib0.000560%
BADD_D00623Dexamethasone0.000363%
BADD_D00723Doxorubicin0.000168%
BADD_D00784Epirubicin--
BADD_D00854Etoposide0.000168%
BADD_D01133Ifosfamide--
BADD_D01136Imatinib0.000895%
BADD_D01137Imatinib mesylate--
BADD_D01217Itraconazole0.004008%
BADD_D01253Lenalidomide0.011019%
BADD_D01392Mercaptopurine0.001041%
BADD_D01418Methotrexate0.000171%
BADD_D01567Nilotinib0.000862%
BADD_D01599Olanzapine0.000421%
BADD_D01601Olaparib0.000112%
BADD_D01662Pamidronic acid--
BADD_D01735Pergolide--
BADD_D01736Pergolide mesylate--
BADD_D01799Ponatinib0.001231%
BADD_D01831Prednisolone0.000105%
BADD_D01978Ruxolitinib0.000206%
BADD_D02150Temozolomide0.000168%
BADD_D02192Thalidomide0.000482%
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
ADR Term Drug Name Target